10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?

ConclusionThis paper is one of the first to estimate the implicit WTP for prescription pharmaceuticals post-AMNOG and suggests that the WTP may vary between different therapeutic areas. Additionally, making different assumptions (approach A versus approach B) with regard to the assumed effectiveness in indication areas that had been declared as having no additional benefit by the FJC may explain the different perspectives of decision-makers and of the pharmaceutical industry on the value of a pharmaceutical.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research